The dıagnostıc Value of Serum autotaxın Level ın Colorectal Cancer

NCT ID: NCT06091592

Last Updated: 2023-10-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

129 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-30

Study Completion Date

2021-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer is one of the most common causes of cancer-related death. Early diagnosis is extremely important in terms of treatment and mortality. In this study, we investigated the diagnostic value of serum autotaxin levels in colorectal cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Colorectal cancer (CRC) is the third most common type of cancer worldwide. Among the causes of death due to cancer; it is the second most common among both genders with a rate of 9.2% after lung cancer . Early detection of the disease is important for survival. National screening programs attempt to detect this disease at an early stage.

Autotaxin (ATX) molecule is a member of the nucleotide pyrophosphatase/phosphodiesterase enzyme family (ENNP), It is secreted at 125 kDa, has lysophospholipase D activity in the lysophosphatidic acid (LPA) pathway, and is located at the 24th locus of the long arm of the 8th chromosome. This is also called ENPP2. It was discovered to be an autocrine motility-stimulating factor released by human melanoma A-2058 cells . Lysophosphatidic acid (LPA) is a lipid signalling molecule located in the cell membrane. LPA functions as an autocrine/paracrine messenger through at least six G protein-coupled receptors (GPCR) known as LPA 1-6. It plays physiologically important roles in various cellular processes, including wound healing, differentiation, cell proliferation, and migration. The role of ATX in the bioactivity of LPA is correlated with the lysophosphatidyl-D (lysoPLD) activity of ATX. ATX molecule; With this enzyme activity, it plays a fundamental role in the conversion of lysophosphatidylcholine to lysophosphatidic acid . Many studies have demonstrated the biological effects of the autotaxin-lysophosphatidic acid (ATX-LPA) signalling pathway in cancer. In vitro and in vivo studies have shown that increased ATX-LPA signalling contributes to cancer initiation and progression. Current evidence supports the role of the ATX-LPA signalling pathway in the proliferation, invasion, adhesion, and angiogenesis of cells, and is effective in cancer development and metastasis. Increased ATX expression has been reported in various cancers, such as glioblastoma, hepatocellular and thyroid carcinomas, breast, pancreatic, colon, and hematological cancers .

The ATX molecule has the feature of being a molecule that will be effective in the future, not only in the diagnosis of cancer, but also in the treatment process and to be studied extensively. in this study, we aimed to examine the diagnostic and biological behaviour relationship between serum ATX levels and colorectal cancer and to determine the cut-off value for serum ATX levels in colorectal cancer.

Serum ATX levels were compared between the patient and control groups. ATX levels were analysed in subgroups formed according to the demographic, clinical, pathological, and laboratory characteristics of the patient group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colo-rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient ( cancer)

. The colorectal cancer patient group included clinical stage 1-3 patients of both sexes. Patients with metastatic disease, those who received neoadjuvant therapy, those who received systemic chemoradiotherapy, those who had any known systemic inflammatory or autoimmune disease, those with another concurrent malignancy, and those who had been previously diagnosed and treated for another malignancy were excluded from the study.

Serum autotaxın levels

Intervention Type OTHER

Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.

Control (healthy volunteer)

The control group included healthy volunteers who had undergone screening colonoscopy within the last month, had no pathology, had not been diagnosed with any malignant disease before, had no known systemic inflammatory or autoimmune disease, and had not been diagnosed with inflammatory bowel disease.

Serum autotaxın levels

Intervention Type OTHER

Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serum autotaxın levels

Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* stage 1-3 colorectal cancer
* control group included healthy volunteers who had undergone screening colonoscopy within the last month , had no pathology,

Exclusion Criteria

* metastatic disease,
* received neoadjuvant therapy
* received systemic chemoradiotherapy
* had any known systemic inflammatory or autoimmune disease
* had a with another concurrent malignancy
* had been previously diagnosed and treated for another malignancy
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Diskapi Yildirim Beyazit Education and Research Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

İsmail Oskay Kaya

PROFESSOR

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ismail o kaya

Role: PRINCIPAL_INVESTIGATOR

Dışkapı Yıldırım Beyazıt training and research hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dışkapı Yıldırım Beyazıt training and research hospital

Ankara, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DYB-GC-AB-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.